Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Current Deferred Revenue (2016 - 2025)

Plus Therapeutics has reported Current Deferred Revenue over the past 12 years, most recently at $927000.0 for Q4 2025.

  • Quarterly Current Deferred Revenue changed 0.0% to $927000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $927000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $927000.0 for FY2025, 0.0% changed from the prior year.
  • Current Deferred Revenue was $927000.0 for Q4 2025 at Plus Therapeutics, down from $2.0 million in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $2.3 million in Q2 2024 and troughed at $247000.0 in Q1 2024.
  • The 3-year median for Current Deferred Revenue is $927000.0 (2024), against an average of $1.2 million.
  • Year-over-year, Current Deferred Revenue tumbled 78.28% in 2024 and then skyrocketed 425.1% in 2025.
  • A 3-year view of Current Deferred Revenue shows it stood at $1.1 million in 2023, then fell by 18.47% to $927000.0 in 2024, then changed by 0.0% to $927000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Current Deferred Revenue are $927000.0 (Q4 2025), $2.0 million (Q3 2025), and $927000.0 (Q2 2025).